XNAS · Healthcare · Biotechnology
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | -0.73 | -1.46 | -100.00% | $78,000 | ❌ Miss | -0.93% | +31.19% | +21.22% |
| 2026-03-09 | Q4 2025 | -0.80 | -1.39 | -73.75% | $947,000 | ❌ Miss | -0.73% | -18.74% | -31.82% |
| 2025-11-06 |
| Q3 2025 |
| -0.70 |
| -1.38 |
| -97.14% |
| $452,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-03-13 | Q4 2024 | -0.83 | -0.40 | +51.81% | $-759,000 | ✅ Beat | -4.88% | -4.09% | -21.73% |
| 2024-11-07 | Q3 2024 | -0.73 | -1.13 | -54.79% | $387,000 | ❌ Miss | -0.10% | -18.09% | +17.57% |
| 2024-05-08 | Q1 2024 | -0.88 | -10.50 | -1093.18% | $5.8M | ❌ Miss | -5.98% | +14.62% | +57.33% |
| 2024-03-07 | Q4 2023 | -0.90 | -41.70 | -4533.33% | $8.3M | ❌ Miss | — | — | — |
| 2023-11-13 | Q3 2023 | -1.80 | -1.80 | +0.00% | $6.6M | ➖ Inline | +0.00% | +4.67% | +31.36% |
Showing last 8 quarters.